Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2987 - Immunohistochemistry (IHC) evaluation of a novel 4-protein prognostic and predictive biomarker panel in endometrial cancer (EC)


08 Oct 2016


Poster Display


Bihani Kularatne


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


B. Kularatne1, R. Arora2, G. Elshstein3, N. Guppy3, A. Kirkwood4, T. Meyer1, R.S. Kristeleit5

Author affiliations

  • 1 Medical Oncology, University College London Cancer Institute, WC1E 6DD - London/GB
  • 2 Histopathology, University College London Hospital, WC1E 6JJ - London/GB
  • 3 Ucl Advanced Diagnostics, University College London Hospital UCLH NHS Foundation Trust, wc1e 6jj - London/GB
  • 4 Cancer Research Uk & Ucl Cancer Trials Centre, UCL - University College London, W1T 4TJ - London/GB
  • 5 Oncology, University College London, Cancer Institute, London/GB


Abstract 2987


EC is common and incidence has increased by 65% in 40 years. There are no validated biomarkers or approved targeted therapies in clinical use. This study evaluates a novel biomarker panel in EC by correlating clinico-pathological features and tumour tissue expression levels of p53, PTEN, phospho-P70S6K (pS6), phospho-Stathmin (pSTMN). pS6 and pSTMN activity is influenced by PI3K/Akt pathway activation which frequently occurs in EC.


The 144 EC patients who had primary surgery from January 2006 to December 2010 at University College London Hospital were retrospectively identified and included in this analysis. Patient characteristics are shown in Table 1. Antibodies for p53, PTEN, pS6 and pSTMN were optimised for use in this study. IHC was performed on surgical resection specimens. Standard scoring methods incorporating percentage of cells stained and staining intensity were applied.


Univariate analysis for disease specific survival (DSS) showed, as expected, non-endometrioid histology, grade 3 tumour, presence of lymphovascular invasion (LVI) or myometrial invasion (MI) and advanced International Federation of Gynaecology and Obstetrics (FIGO) stage conferred poor DSS. The overexpression of p53 and pSTMN was also associated with poor DSS. In multivariate analysis grade 3 histology, MI, p53 and pSTMN overexpression were the only factors that remained significantly associated with poor DSS.

Cox proportional hazard regression model comparing clinico-pathological features and biomarker expression with DSS. NA-Not applicable. HR-Hazard ratio. CI- Confidence interval.

Variable Categories Univariate Analysis Multivariate Analysis
n Deaths HR (95% CI) p value HR(95% CI) p value
Age >65 ≥65 59 85 7 17 1.91 (0.79-4.62) 0.15 3.43 (0.33-35.14) 0.3
Histological sub-type Endometrioid Non-endometrioid 128 16 16 8 4.90 (2.09-11.48)


We demonstrate for the first time that p53 and pSTMN overexpression are independent predictors of DSS in EC and may be useful prognostic biomarkers. Overexpression of pSTMN may predict sensitivity to PI3K pathway inhibitors in EC. Prospective evaluation is warranted in clinical studies.

Clinical trial identification

Legal entity responsible for the study

UCL Cancer Institute


UCL Cancer Institute


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.